ENDOCANNABINOID CEREBROSPINAL FLUID LEVELS IN MIGRAINE 89 4 Supplementary Information Supplementary e-Figure 1 Conflicts of interest statement: G.M. Terwindt reports consultancy support from Novartis, Allergan/Abbvie, Lilly, and Teva, Lundbeck and independent support from Dutch Research Council, the Dutch Heart & Brain Foundations, Dioraphte, and the European Community. A.M.J.M. van den Maagdenberg reports independent support from Schedule 1 Therapeutics, Praxis Precision Medicine, and AbbVie as well as the European Community. The other authors report no disclosures. Acknowledgements: We greatly acknowledge all study participants, the medical students who assisted with recruitment of participants, physicians F. Bakels, N. Pelzer, L.A. Wilbrink and A.A. van der Plas for sample collection. This study was supported by the Netherlands Organization for Scientific Research (VICI grant 918.56.601 and Spinoza 2009 to M.D. Ferrari), the Netherlands Organization for Health Research and Development (Clinical Fellowship 90700217 and Vidi 917-11-31 to G.M. Terwindt), and European Community (EC) FP7-EUROHEADPAIN – no. 602633 (to M.D. Ferrari and A.M.J.M. van den Maagdenberg). A.V.E. Harder, X. Di, R.M. van Dongen, G.L.J. Onderwater, M.D. Ferrari , A.M.J.M. van den Maagdenberg, T. Hankemeier and G.M. Terwindt were responsible for the study concept and design. A.V.E. Harder, W.M. Winter, E.W. van Zwet, A.M.J.M. van den Maagdenberg and G.M. Terwindt contributed to data collection and interpretation. X. Di, E.H.J. Krekels, I. Kohler and A.C. Harms were responsible for the endocannabinoid measurements. A.V.E. Harder and W.M. Winter carried out the statistical analyses under supervision of E.W. van Zwet. A.V.E. Harder wrote the initial draft of the manuscript. All authors critically revised the article and approved the final version for submission.
RkJQdWJsaXNoZXIy MTk4NDMw